Discounted Cash Flow Rating

Buy

Return on Equity Rating

Buy

Debt to Equity Rating

Sell

Price to Earnings Rating

Neutral

Analyst Rating

Buy

Simple Moving Average

Strong Buy

Exponential Moving Average

Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Buy

A

Regency Centers Corporation (REG)

Real Estate Investment Trusts

https://www.regencycenters.com

Regency Centers is the largest shopping center-focused retail REIT. The company's portfolio includes an interest in 480 properties, which includes nearly 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 14% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.

ONE INDEPENDENT DRIVE, SUITE 114
JACKSONVILLE, FL

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/29/1993

Market Cap

12,645,803,475

Shares Outstanding

184,580,000

Weighted SO

184,580,981

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

UBP --.--%

BFS --.--%

ROIC --.--%

RPT --.--%

GTY --.--%

SITC --.--%

BRX --.--%

SKT --.--%

UBA --.--%

Beta

1.2160

Last Div

2.6800

Range

56.29-71.3

Chg

-0.3350

Avg Vol

1019612

Mkt Cap

12645803475

Exch

NASDAQ

Country

US

Phone

904-598-7000

DCF Diff

0.2932

DCF

69.4368

Div Yield

0.0382

P/S

8.9405

EV Multiple

19.4521

P/FV

1.8835

Div Yield %

3.8177

P/E

32.5740

PEG

7.4702

Payout

1.2424

Current Ratio

0.9711

Quick Ratio

1.0103

Cash Ratio

0.1924

DSO

61.1584

DIO

-9.5385

Op Cycle

51.6200

DPO

199.0660

CCC

-147.4460

Gross Margin

0.5592

Op Margin

0.4681

Pretax Margin

0.2807

Net Margin

0.2778

Eff Tax Rate

0.3237

ROA

0.0317

ROE

0.0563

ROCE

0.0553

NI/EBT

0.9896

EBT/EBIT

0.5997

EBIT/Rev

0.4681

Debt Ratio

0.3525

D/E

0.6424

LT Debt/Cap

0.3879

Total Debt/Cap

0.3911

Int Coverage

3.9309

CF/Debt

0.1733

Equity Multi

1.8223

Rec Turnover

5.9681

Pay Turnover

1.8336

Inv Turnover

-38.2661

FA Turnover

4.2897

Asset Turnover

0.1142

OCF/Share

4.1175

FCF/Share

2.6149

Cash/Share

0.5238

OCF/Sales

0.5348

FCF/OCF

0.6351

CF Coverage

0.1733

ST Coverage

13.0053

CapEx Coverage

2.7403

Div&CapEx Cov

0.9898

P/BV

1.8835

P/B

1.8835

P/S

8.9405

P/E

32.5740

P/FCF

26.3255

P/OCF

16.9218

P/CF

16.9218

PEG

7.4702

P/S

8.9405

EV Multiple

19.4521

P/FV

1.8835

DPS

2.6600

Latest Headlines (EST)

GlobeNewswire Inc. Jun 07, 22:30 Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color GlobeNewswire Inc. May 30, 05:00 Communiqué de presse : L’itépekimab a satisfait au critère d’évaluation principal dans l’une des deux études de phase 3 sur la BPCO GlobeNewswire Inc. May 30, 05:00 Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials GlobeNewswire Inc. May 30, 05:00 Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies The Motley Fool Mar 25, 22:47 Why Pharma and Biotech Stocks Got Thrashed on Tuesday GlobeNewswire Inc. Mar 23, 17:41 DonAlt Turns Bullish On XRP Targeting Massive Gains As XRPTurbo Presale Hits 50% Of Hardcap GlobeNewswire Inc. Mar 12, 01:32 Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem GlobeNewswire Inc. Mar 01, 20:13 REGN ?????????????????? ROSEN ???? 10 ?????? Regeneron Pharmaceuticals, Inc. ????? REGN ??????????????? 3 ? 10 ?????? GlobeNewswire Inc. Mar 01, 20:13 REGN FINAL DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action – REGN GlobeNewswire Inc. Feb 27, 01:10 REGN DEADLINE ALERT: Regeneron Pharmaceuticals (REGN) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 10th Deadline in Securities Class Action GlobeNewswire Inc. Feb 23, 19:03 ROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN GlobeNewswire Inc. Feb 21, 00:26 ROSEN, LEADING TRIAL ATTORNEYS, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN GlobeNewswire Inc. Feb 19, 00:53 REGN STOCK NEWS: Robbins LLP Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025 GlobeNewswire Inc. Feb 18, 05:59 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP) GlobeNewswire Inc. Feb 12, 23:57 Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit– Hagens Berman GlobeNewswire Inc. Feb 12, 02:04 ROSEN, A LEADING LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN GlobeNewswire Inc. Feb 09, 04:34 ROSEN, A LEADING LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN GlobeNewswire Inc. Feb 08, 22:40 EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting GlobeNewswire Inc. Feb 08, 20:55 Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals GlobeNewswire Inc. Jan 29, 02:02 ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN

Revenue Product Segmentation

Dividend History

Cash Value Ex-Dividend Date Declaration Date Record Date Pay Date
0.67 06/12/2024 05/02/2024 06/12/2024 07/03/2024
0.67 03/12/2024 02/07/2024 03/13/2024 04/03/2024
0.67 12/13/2023 11/02/2023 12/14/2023 01/03/2024
0.65 09/13/2023 08/03/2023 09/14/2023 10/04/2023
0.65 06/13/2023 05/02/2023 06/14/2023 07/06/2023
0.65 03/14/2023 02/09/2023 03/15/2023 04/05/2023
0.65 12/15/2022 11/02/2022 12/16/2022 01/04/2023
0.62 09/14/2022 08/02/2022 09/15/2022 10/04/2022
0.62 06/14/2022 04/29/2022 06/15/2022 07/06/2022
0.62 03/14/2022 02/09/2022 03/15/2022 04/05/2022
0.62 12/15/2021 11/02/2021 12/16/2021 01/05/2022
0.60 09/14/2021 08/04/2021 09/15/2021 10/05/2021
0.60 06/14/2021 05/05/2021 06/15/2021 07/06/2021
0.60 03/12/2021 02/10/2021 03/15/2021 04/06/2021
0.60 12/15/2020 11/04/2020 12/16/2020 01/05/2021
0.60 08/13/2020 07/29/2020 08/14/2020 08/24/2020
0.60 05/15/2020 05/04/2020 05/18/2020 05/26/2020
0.60 02/21/2020 02/04/2020 02/24/2020 03/05/2020
0.58 11/08/2019 10/29/2019 11/12/2019 11/22/2019
0.58 08/09/2019 07/31/2019 08/12/2019 08/22/2019
0.58 05/10/2019 04/30/2019 05/13/2019 05/23/2019
0.58 02/22/2019 02/13/2019 02/25/2019 03/07/2019
0.56 11/13/2018 10/25/2018 11/14/2018 11/28/2018
0.56 08/14/2018 07/31/2018 08/15/2018 08/29/2018
0.56 05/15/2018 04/30/2018 05/16/2018 05/30/2018
0.56 02/16/2018 02/08/2018 02/20/2018 03/02/2018
0.53 11/14/2017 10/31/2017 11/15/2017 11/29/2017
0.53 08/14/2017 08/04/2017 08/16/2017 08/30/2017
0.53 05/18/2017 05/09/2017 05/22/2017 05/31/2017
0.51 02/22/2017 02/09/2017 02/24/2017 03/01/2017
0.50 11/14/2016 11/01/2016 11/16/2016 11/30/2016
0.50 08/15/2016 08/02/2016 08/17/2016 08/31/2016
0.50 05/16/2016 05/04/2016 05/18/2016 06/01/2016
0.50 02/18/2016 02/11/2016 02/22/2016 03/03/2016
0.48 11/16/2015 11/02/2015 11/18/2015 12/02/2015
0.48 08/17/2015 08/06/2015 08/19/2015 09/02/2015
0.48 05/18/2015 05/07/2015 05/20/2015 06/03/2015
0.48 02/19/2015 01/15/2015 02/23/2015 03/05/2015
0.47 11/17/2014 11/04/2014 11/19/2014 12/03/2014
0.47 08/18/2014 08/07/2014 08/20/2014 09/03/2014
0.47 05/19/2014 05/08/2014 05/21/2014 06/04/2014
0.47 02/20/2014 02/12/2014 02/24/2014 03/06/2014
0.46 11/08/2013 10/31/2013 11/13/2013 11/27/2013
0.46 08/12/2013 08/01/2013 08/14/2013 08/28/2013
0.46 05/20/2013 05/07/2013 05/22/2013 06/05/2013
0.46 02/11/2013 01/31/2013 02/13/2013 02/27/2013
0.46 11/09/2012 11/02/2012 11/14/2012 11/28/2012
0.46 08/13/2012 08/01/2012 08/15/2012 08/29/2012
0.46 05/14/2012 05/04/2012 05/16/2012 05/30/2012
0.46 02/13/2012 02/02/2012 02/15/2012 02/29/2012
0.46 11/14/2011 11/07/2011 11/16/2011 11/30/2011
0.46 08/15/2011 08/05/2011 08/17/2011 08/31/2011
0.46 05/16/2011 05/06/2011 05/18/2011 06/01/2011
0.46 02/14/2011 02/04/2011 02/16/2011 03/02/2011
0.46 11/15/2010 11/05/2010 11/17/2010 12/01/2010
0.46 08/16/2010 08/05/2010 08/18/2010 09/01/2010
0.46 05/17/2010 05/06/2010 05/19/2010 06/02/2010
0.46 02/12/2010 02/05/2010 02/17/2010 03/03/2010
0.46 11/16/2009 11/02/2009 11/18/2009 12/02/2009
0.46 08/17/2009 08/06/2009 08/19/2009 09/02/2009
0.46 05/18/2009 05/08/2009 05/20/2009 06/03/2009
0.72 02/13/2009 02/03/2009 02/18/2009 03/04/2009
0.72 11/17/2008 11/05/2008 11/19/2008 12/03/2008
0.72 08/18/2008 08/05/2008 08/20/2008 09/03/2008
0.72 05/19/2008 05/06/2008 05/21/2008 06/04/2008
0.72 02/15/2008 02/06/2008 02/20/2008 03/05/2008
0.66 11/09/2007 11/01/2007 11/14/2007 11/28/2007
0.66 08/13/2007 08/02/2007 08/15/2007 08/29/2007
0.66 05/14/2007 05/03/2007 05/16/2007 05/30/2007
0.66 02/12/2007 02/01/2007 02/14/2007 02/28/2007
0.60 11/13/2006 11/02/2006 11/15/2006 11/29/2006
0.60 08/14/2006 08/03/2006 08/16/2006 08/30/2006
0.60 05/15/2006 05/04/2006 05/17/2006 05/31/2006
0.60 02/13/2006 02/02/2006 02/15/2006 03/01/2006
0.55 11/10/2005 10/31/2005 11/15/2005 11/29/2005
0.55 08/12/2005 08/04/2005 08/16/2005 08/30/2005
0.55 05/16/2005 05/04/2005 05/18/2005 06/01/2005
0.55 02/11/2005 02/03/2005 02/15/2005 03/01/2005
0.53 11/08/2004 10/28/2004 11/10/2004 11/24/2004
0.53 08/09/2004 07/30/2004 08/11/2004 08/25/2004
0.53 05/10/2004 04/30/2004 05/12/2004 05/26/2004
0.53 02/09/2004 01/29/2004 02/11/2004 02/25/2004
0.52 11/17/2003 11/04/2003 11/19/2003 12/03/2003
0.52 08/22/2003 08/12/2003 08/26/2003 09/09/2003
0.52 05/19/2003 05/06/2003 05/21/2003 06/04/2003
0.52 02/14/2003 02/05/2003 02/19/2003 03/05/2003
0.51 11/15/2002 11/04/2002 11/19/2002 12/03/2002
0.51 08/19/2002 08/07/2002 08/21/2002 09/04/2002
0.51 05/09/2002 05/08/2002 05/13/2002 05/28/2002
0.51 02/08/2002 02/06/2002 02/12/2002 02/26/2002
0.50 11/07/2001 10/31/2001 11/12/2001 11/26/2001
0.50 08/09/2001 07/31/2001 08/13/2001 08/27/2001
0.50 05/09/2001 05/04/2001 05/11/2001 05/25/2001
0.50 02/08/2001 01/30/2001 02/12/2001 02/27/2001
0.48 11/09/2000 11/06/2000 11/13/2000 11/28/2000
0.48 08/09/2000 08/01/2000 08/11/2000 08/25/2000
0.48 05/10/2000 05/03/2000 05/12/2000 05/26/2000
0.48 02/09/2000 02/02/2000 02/11/2000 02/25/2000
0.46 11/08/1999 11/03/1999 11/10/1999 11/24/1999
0.46 08/10/1999 07/30/1999 08/12/1999 08/26/1999
0.46 05/10/1999 11/30/-0001 05/12/1999 05/26/1999
0.46 02/10/1999 02/02/1999 02/12/1999 02/26/1999
0.44 11/06/1998 10/27/1998 11/10/1998 11/24/1998
0.44 08/10/1998 07/28/1998 08/12/1998 08/26/1998
0.44 05/12/1998 04/28/1998 05/14/1998 05/28/1998
0.44 02/10/1998 02/03/1998 02/12/1998 02/26/1998
0.42 11/07/1997 10/27/1997 11/12/1997 11/26/1997
0.42 08/08/1997 07/22/1997 08/12/1997 08/26/1997
0.42 05/12/1997 04/29/1997 05/14/1997 05/28/1997
0.42 02/10/1997 01/28/1997 02/12/1997 02/26/1997
0.40 11/06/1996 10/29/1996 11/11/1996 11/25/1996
0.40 08/08/1996 07/30/1996 08/12/1996 08/26/1996
0.40 05/09/1996 04/30/1996 05/13/1996 05/28/1996
0.40 02/08/1996 01/29/1996 02/12/1996 02/26/1996
0.40 11/08/1995 10/31/1995 11/10/1995 11/27/1995
0.40 08/09/1995 07/27/1995 08/11/1995 08/25/1995
0.40 05/08/1995 05/03/1995 05/12/1995 05/26/1995
0.40 02/07/1995 11/30/-0001 02/13/1995 02/27/1995
0.40 11/04/1994 11/30/-0001 11/11/1994 11/29/1994
0.38 08/08/1994 11/30/-0001 08/12/1994 08/26/1994
0.38 05/09/1994 11/30/-0001 05/13/1994 05/27/1994
0.23 02/07/1994 11/30/-0001 02/11/1994 02/25/1994